Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses
Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, whi...
Saved in:
Published in | Allergy (Copenhagen) Vol. 78; no. 5; pp. 1307 - 1318 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Blackwell Publishing Ltd
01.05.2023
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias.
Objective
The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction.
Method
As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.
Results
An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).
Conclusion
We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.
An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol |
---|---|
AbstractList | An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias.BACKGROUNDThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias.The aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction.OBJECTIVEThe aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction.As part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.METHODAs part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.An intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).RESULTSAn intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.CONCLUSIONWe demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias. The aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction. As part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. An intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. BackgroundThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias.ObjectiveThe aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction.MethodAs part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.ResultsAn intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).ConclusionWe demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. BACKGROUND: The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. OBJECTIVE: The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. METHOD: As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. RESULTS: An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). CONCLUSION: We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. Objective The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. Method As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. Results An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). Conclusion We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol |
Author | Ylescupidez, Alyssa Clare Mills, E. N. Campbell, Dianne E. Roberts, Graham Perkin, Michael R. Du Toit, George Lack, Gideon Beyer, Kirsten Bellach, Johanna Craven, Joanna Bahnson, Henry T. Logan, Kirsty Ree, Ronald |
AuthorAffiliation | 5 School of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology University of Manchester Manchester UK 7 University of Southampton and Southampton NIHR Biomedical Research Centre Southampton UK 8 Departments of Experimental Immunology and of Otorhinolaryngology Amsterdam University Medical Centers Amsterdam Netherlands 6 The Population Health Research Institute St George's University of London London UK 1 Department of Women and Children's Health, School of Life Course and Population Sciences King's College London London UK 3 Charité Universitätsmedizin Berlin Berlin Germany 4 Children's Hospital at Westmead Westmead New South Wales Australia 2 Immune Tolerance Network Benaroya Research Institute Seattle Washington USA |
AuthorAffiliation_xml | – name: 6 The Population Health Research Institute St George's University of London London UK – name: 3 Charité Universitätsmedizin Berlin Berlin Germany – name: 5 School of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology University of Manchester Manchester UK – name: 8 Departments of Experimental Immunology and of Otorhinolaryngology Amsterdam University Medical Centers Amsterdam Netherlands – name: 2 Immune Tolerance Network Benaroya Research Institute Seattle Washington USA – name: 7 University of Southampton and Southampton NIHR Biomedical Research Centre Southampton UK – name: 1 Department of Women and Children's Health, School of Life Course and Population Sciences King's College London London UK – name: 4 Children's Hospital at Westmead Westmead New South Wales Australia |
Author_xml | – sequence: 1 givenname: Kirsty surname: Logan fullname: Logan, Kirsty organization: King's College London – sequence: 2 givenname: Henry T. surname: Bahnson fullname: Bahnson, Henry T. organization: Benaroya Research Institute – sequence: 3 givenname: Alyssa surname: Ylescupidez fullname: Ylescupidez, Alyssa organization: Benaroya Research Institute – sequence: 4 givenname: Kirsten surname: Beyer fullname: Beyer, Kirsten organization: Charité Universitätsmedizin Berlin – sequence: 5 givenname: Johanna surname: Bellach fullname: Bellach, Johanna organization: Charité Universitätsmedizin Berlin – sequence: 6 givenname: Dianne E. surname: Campbell fullname: Campbell, Dianne E. organization: Children's Hospital at Westmead – sequence: 7 givenname: Joanna surname: Craven fullname: Craven, Joanna organization: King's College London – sequence: 8 givenname: George surname: Du Toit fullname: Du Toit, George organization: King's College London – sequence: 9 givenname: E. N. surname: Clare Mills fullname: Clare Mills, E. N. organization: University of Manchester – sequence: 10 givenname: Michael R. surname: Perkin fullname: Perkin, Michael R. organization: St George's University of London – sequence: 11 givenname: Graham orcidid: 0000-0003-2252-1248 surname: Roberts fullname: Roberts, Graham organization: University of Southampton and Southampton NIHR Biomedical Research Centre – sequence: 12 givenname: Ronald surname: Ree fullname: Ree, Ronald organization: Amsterdam University Medical Centers – sequence: 13 givenname: Gideon orcidid: 0000-0001-7350-4021 surname: Lack fullname: Lack, Gideon email: gideon.lack@kcl.ac.uk organization: King's College London |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36435990$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkk1v1DAQhi1URLeFA38AWeJCD2n9lXV8QlXVQqWVuLRny3Emi4vXDnYCyr_H291FUBXhi-XxM69n_M4JOgoxAEJvKTmnZV0Y789pXSv5Ai0oV02llKqP0IJQUlei5s0xOsn5gRAimSKv0DFfCl4rRRYoXJvkZ-zCmGI32dHFgGOPBzBhGnGCEoN8OJZ3IK1nbGyKOePk8je8TnEachHAQ4weOmxCh62ZsvEl2EOCYKEEjZ8z5NfoZW98hjf7_RTd31zfXX2uVl8-3V5driorpJSVIXzZqQY44ZRTBVwQZhte875tGQjBDKGqEaJtemqAsLYFULBs5dIa1QrOT9HHne4wtRvoLJT-jNdDchuTZh2N03_fBPdVr-MPTQkjjLK6KHzYK6T4fYI86o3LFrw3AeKUNWu4YFRwSf6PSkFqwqUUBX3_BH2IUyqfsxUkUjaKSVqod39W_7vsg20FuNgBj0Yk6LV1o9maV5pxvnSht4Ohi2H6cTBKxtmTjIPoc-xe_afzMP8b1Jer1S7jF_HQyGk |
CitedBy_id | crossref_primary_10_1016_j_jaip_2024_05_028 crossref_primary_10_1007_s15007_024_6250_0 crossref_primary_10_1111_all_15676 crossref_primary_10_1111_all_16025 crossref_primary_10_1111_all_16069 crossref_primary_10_1111_all_16429 crossref_primary_10_1001_jamapediatrics_2023_0142 crossref_primary_10_3389_falgy_2025_1562667 crossref_primary_10_1097_ACI_0000000000000983 crossref_primary_10_3389_fsci_2024_1279192 crossref_primary_10_1016_j_jaci_2023_11_918 crossref_primary_10_1111_apa_16763 crossref_primary_10_29219_fnr_v68_10456 crossref_primary_10_1016_j_tjnut_2023_06_015 crossref_primary_10_1016_j_anai_2024_06_002 crossref_primary_10_1007_s13671_024_00452_w crossref_primary_10_1016_j_jaip_2024_06_022 crossref_primary_10_3389_falgy_2023_1219268 crossref_primary_10_3390_allergies5010005 crossref_primary_10_1016_j_anai_2023_05_031 crossref_primary_10_3390_allergies4040016 crossref_primary_10_4168_aair_2023_15_4_419 crossref_primary_10_1016_j_jaip_2023_10_013 crossref_primary_10_1111_cea_14454 crossref_primary_10_1111_cea_14452 crossref_primary_10_3389_falgy_2024_1439303 crossref_primary_10_1111_pai_14094 |
Cites_doi | 10.1016/j.jaci.2008.08.039 10.1056/NEJMoa1514210 10.5694/mja2.12102 10.1016/j.jaci.2012.09.015 10.1016/j.jaci.2020.01.015 10.1016/S0140-6736(22)00687-0 10.1542/peds.106.S4.1274a 10.1016/j.jaip.2015.12.016 10.1016/j.jaci.2016.10.010 10.1016/j.jclinepi.2018.06.009 10.1016/j.jaci.2019.06.046 10.1016/j.jaci.2015.12.1322 10.1111/j.1541-0420.2005.00377.x 10.1016/j.jaci.2020.01.016 10.1001/jama.2016.12623 10.1056/NEJMsm1605385 10.1056/NEJMoa1414850 10.1016/j.jaci.2019.07.032 10.1136/bmj.319.7211.652 10.1111/all.13127 10.1111/pai.13496 10.1002/sim.1903 |
ContentType | Journal Article |
Copyright | 2022 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2022 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. – notice: 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. – notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 7S9 L.6 5PM |
DOI | 10.1111/all.15597 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts AGRICOLA |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Logan et al |
EISSN | 1398-9995 |
EndPage | 1318 |
ExternalDocumentID | PMC10202125 36435990 10_1111_all_15597 ALL15597 |
Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institute of Allergy and Infectious Diseases – fundername: Medical Research Council – fundername: National Peanut Board – fundername: The Davis Foundation funderid: 1152998 – fundername: European Union – fundername: Food Allergy Research and Education – fundername: National Institute for Health Research – fundername: Food Standards Agency – fundername: Asthma UK – fundername: Medical Research Council grantid: MC_G1001205 – fundername: NIAID NIH HHS grantid: UM1 AI109565 – fundername: NIAID NIH HHS grantid: HHSN272200800029C – fundername: NIAID NIH HHS grantid: N01AI15416 – fundername: ; – fundername: The Davis Foundation grantid: 1152998 |
GroupedDBID | .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7T5 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 7S9 L.6 5PM |
ID | FETCH-LOGICAL-c4777-a036d98e3031319e3402c8353fbb2e442a019844b8f1ae02bbee9e6b76ca9b433 |
IEDL.DBID | DR2 |
ISSN | 0105-4538 1398-9995 |
IngestDate | Thu Aug 21 18:36:47 EDT 2025 Fri Jul 11 18:27:40 EDT 2025 Fri Jul 11 10:11:30 EDT 2025 Sat Jul 19 05:42:19 EDT 2025 Wed Feb 19 02:23:43 EST 2025 Tue Jul 01 02:54:30 EDT 2025 Thu Apr 24 22:57:04 EDT 2025 Wed Jan 22 16:21:36 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | causal inference analysis early introduction peanut allergy prevention |
Language | English |
License | Attribution 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4777-a036d98e3031319e3402c8353fbb2e442a019844b8f1ae02bbee9e6b76ca9b433 |
Notes | Kirsty Logan and Henry T. Bahnson contributed equally to this manuscript. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ORCID | 0000-0003-2252-1248 0000-0001-7350-4021 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15597 |
PMID | 36435990 |
PQID | 2807789271 |
PQPubID | 34098 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10202125 proquest_miscellaneous_2834214370 proquest_miscellaneous_2740503774 proquest_journals_2807789271 pubmed_primary_36435990 crossref_citationtrail_10_1111_all_15597 crossref_primary_10_1111_all_15597 wiley_primary_10_1111_all_15597_ALL15597 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2023 |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
PublicationDecade | 2020 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Zurich – name: Hoboken |
PublicationTitle | Allergy (Copenhagen) |
PublicationTitleAlternate | Allergy |
PublicationYear | 2023 |
Publisher | Blackwell Publishing Ltd John Wiley and Sons Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley and Sons Inc |
References | 2004; 23 2018; 103 1998 2004 2020; 145 2005; 61 2008; 122 2019; 144 2017; 139 2022; 399 2015; 372 2016; 4 2017; 72 2021; 32 2021 2016; 316 2000; 106 2017; 77 2016; 374 2016 2016; 137 2014 2013; 131 1999; 319 2019; 210 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 SAS Institute Inc (e_1_2_9_18_1) 2016 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 Wooldridge JM (e_1_2_9_17_1) 2004 e_1_2_9_2_1 Committee on Toxicity of Chemicals in Food CpatE, Department of Health (e_1_2_9_3_1) 1998 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 |
References_xml | – volume: 399 start-page: 2398 issue: 10344 year: 2022 end-page: 2411 article-title: Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster‐randomised trial publication-title: Lancet – volume: 77 start-page: 1391 issue: 14 year: 2017 end-page: 1398 article-title: Per‐protocol analyses of pragmatic trials publication-title: N Engl J Med – volume: 319 start-page: 652 year: 1999 end-page: 653 article-title: Can it work? Does it work? Is it worth it? publication-title: BMJ – year: 2021 – volume: 316 start-page: 1181 issue: 11 year: 2016 end-page: 1192 article-title: Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease. A systematic review and meta‐analysis publication-title: JAMA – volume: 137 start-page: 1477 issue: 5 year: 2016 end-page: 1486 article-title: Enquiring about tolerance (EAT) study: feasibility of an early allergenic food introduction regimen publication-title: J Allergy Clin Immunol – volume: 144 start-page: 1595 issue: 6 year: 2019 end-page: 1605 article-title: Factors influencing adherence in a trial of early introduction of allergenic food publication-title: J Allergy Clin Immunol – year: 2016 – volume: 374 start-page: 1733 issue: 18 year: 2016 end-page: 1743 article-title: Randomized trial of introduction of allergenic foods in breast‐fed infants publication-title: N Engl J Med – volume: 61 start-page: 962 year: 2005 end-page: 973 article-title: Doubly robust estimation in missing data and causal inference models publication-title: Biometrics – volume: 106 start-page: 1274 issue: 5 year: 2000 article-title: American Academy of Pediatrics recommendations for complementary feeding publication-title: Pediatrics – year: 1998 – volume: 139 start-page: 29 issue: 1 year: 2017 end-page: 44 article-title: Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel publication-title: J Allergy Clin Immunol – volume: 372 start-page: 803 issue: 9 year: 2015 end-page: 813 article-title: Randomized trial of peanut consumption in infants at risk for peanut allergy publication-title: N Engl J Med – start-page: 2 year: 2014 – volume: 210 start-page: 89 issue: 2 year: 2019 end-page: 93 article-title: The Australasian Society of Clinical Immunology and Allergy infant feeding for allergy prevention guidelines publication-title: Med J Aust – volume: 72 start-page: 1267 issue: 8 year: 2017 end-page: 1271 article-title: Letter of response to Greenhawt et al. 'LEAPing through the looking glass: secondary analysis of the effect of skin test size and age of introduction on peanut tolerance after early peanut introduction' publication-title: Allergy – volume: 131 start-page: 135 issue: 1 year: 2013 end-page: 143 article-title: Identifying infants at high risk of peanut allergy: the learning early about peanut allergy (LEAP) screening study publication-title: J Allergy Clin Immunol – volume: 23 start-page: 2937 year: 2004 end-page: 2960 article-title: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study publication-title: Stat Med – year: 2004 – volume: 103 start-page: 10 year: 2018 end-page: 21 article-title: Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials publication-title: J Clin Epidemiol – volume: 144 start-page: 1327 issue: 5 year: 2019 end-page: 1335 article-title: Earlier ingestion of peanut after changes to infant feeding guidelines: the EarlyNuts study publication-title: J Allergy Clin Immunol – volume: 145 start-page: 1305 issue: 4 year: 2020 article-title: Low‐risk infants may still benefit from allergenic food consumption publication-title: J Allergy Clin Immunol – volume: 32 start-page: 843 issue: 5 year: 2021 end-page: 858 article-title: European academy of allergy and clinical immunology food allergy and anaphylaxis guidelines group. EAACI guideline: preventing the development of food allergy in infants and young children (2020 update) publication-title: Pediatr Allergy Immunol – volume: 145 start-page: 1305 issue: 4 year: 2020 end-page: 1306 article-title: Letter of response to Iglesia et al. “Low‐risk infants may still benefit from allergenic food consumption” publication-title: J Allergy Clin Immunol – volume: 122 start-page: 984 issue: 5 year: 2008 end-page: 991 article-title: Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy publication-title: J Allergy Clin Immunol – volume: 4 start-page: 221 issue: 2 year: 2016 end-page: 225 article-title: The complexities of early Peanut introduction for the practicing allergist publication-title: J Allergy Clin Immunol Pract – ident: e_1_2_9_5_1 doi: 10.1016/j.jaci.2008.08.039 – ident: e_1_2_9_7_1 doi: 10.1056/NEJMoa1514210 – ident: e_1_2_9_26_1 doi: 10.5694/mja2.12102 – ident: e_1_2_9_13_1 doi: 10.1016/j.jaci.2012.09.015 – volume-title: Econometric Analysis of Cross Section and Panel Data year: 2004 ident: e_1_2_9_17_1 – ident: e_1_2_9_23_1 doi: 10.1016/j.jaci.2020.01.015 – ident: e_1_2_9_20_1 doi: 10.1016/S0140-6736(22)00687-0 – ident: e_1_2_9_4_1 doi: 10.1542/peds.106.S4.1274a – ident: e_1_2_9_19_1 – ident: e_1_2_9_27_1 doi: 10.1016/j.jaip.2015.12.016 – volume-title: COT Consumer Products and the Environment–Peanut Allergy. DoH year: 1998 ident: e_1_2_9_3_1 – ident: e_1_2_9_10_1 doi: 10.1016/j.jaci.2016.10.010 – volume-title: SAS/STAT 14.2 User's Guide year: 2016 ident: e_1_2_9_18_1 – ident: e_1_2_9_21_1 – ident: e_1_2_9_11_1 doi: 10.1016/j.jclinepi.2018.06.009 – ident: e_1_2_9_9_1 doi: 10.1016/j.jaci.2019.06.046 – ident: e_1_2_9_14_1 doi: 10.1016/j.jaci.2015.12.1322 – ident: e_1_2_9_15_1 doi: 10.1111/j.1541-0420.2005.00377.x – ident: e_1_2_9_22_1 doi: 10.1016/j.jaci.2020.01.016 – ident: e_1_2_9_8_1 doi: 10.1001/jama.2016.12623 – ident: e_1_2_9_12_1 doi: 10.1056/NEJMsm1605385 – ident: e_1_2_9_6_1 doi: 10.1056/NEJMoa1414850 – ident: e_1_2_9_25_1 doi: 10.1016/j.jaci.2019.07.032 – ident: e_1_2_9_24_1 doi: 10.1136/bmj.319.7211.652 – ident: e_1_2_9_28_1 doi: 10.1111/all.13127 – ident: e_1_2_9_2_1 doi: 10.1111/pai.13496 – ident: e_1_2_9_16_1 doi: 10.1002/sim.1903 |
SSID | ssj0007290 |
Score | 2.5154672 |
Snippet | Background
The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA).... The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the... BackgroundThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA).... BACKGROUND: The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA).... An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1307 |
SubjectTerms | Allergens Allergies Arachis causal inference analysis Child Children Clinical trials early introduction Eczema Food allergies Humans hypersensitivity infancy Infant Original ORIGINAL ARTICLES patients peanut allergy prevention Peanut Hypersensitivity - epidemiology Peanut Hypersensitivity - prevention & control peanuts Pediatrics protective effect relative risk Risk Factors Risk groups risk reduction Statistical analysis |
Title | Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15597 https://www.ncbi.nlm.nih.gov/pubmed/36435990 https://www.proquest.com/docview/2807789271 https://www.proquest.com/docview/2740503774 https://www.proquest.com/docview/2834214370 https://pubmed.ncbi.nlm.nih.gov/PMC10202125 |
Volume | 78 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb9QwEIdHpQfEhUfLI6VUpuqBS1ZJbK9jcaoQVYVahFAr9YAU2Y5DV6yyaLM5lL-eGedBl7YI9bZZzzpx4ln_Ys98BjjgVjqZT5M4LWmZEQV1rFHmxihOKsOVT01C-c6nn6fH5-LThbzYgPdDLkzHhxgn3Mgzwv81ObixzTUnN_P5hNbUKJOcYrVIEH39g45S_fwK6odYoFf3VCGK4hl_uT4W3RCYN-Mkr-vXMAAdPYFvw6V3cSc_Ju3KTtyvv6iO92zbU3jcC1N22PWkZ7Dh6y14eNovvW9DHVDIbEaR7WWHnGWLitFMfrtiSyLA-mY4pA1alt-vmAkNZxS_zkL-SIMVMNrWy5fM1CVzpm3wrLMh7RC_JEiKb57D-dHHsw_Hcb9ZQ-yEUio2OBSWOvecYJCp9hxfTB3KO15Zm3khMoNiMhfC5lVqfJJZ6732U6umzmgrOH8Bm_Wi9q-AlS4rpTJSEY1Opk5XWgudcIm1a5PbCN4Nj61wPcmcNtSYF8MbDbayCPcvgv3R9GeH77jNaHd49kXvwU1BlCCV60ylEbwdi9H3aEHF1H7Roo0ShNNBBf0Pm5yLDEWpSiJ42XWn8Uo4ykGJciCCfK2jjQbE_l4vqWeXgQGOupDg_BLvRehId7euODw5CR92_t_0NTzC6vvAzl3YXC1b_wbF18ruwYNMfNkLvvYbtMcsgg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lj9MwEIdHyyIBF96PwAIGceCSKontOpa4rBCrAu0e0K60FxTZjgMVVYqa5gB_PTPOgy0LCHFrmsnDiSf-2R5_A_CCW-lkPk3itKRpRhTUsUaZG6M4qQxXPjUJrXdeHE9np-LdmTzbg1fDWpiODzEOuJFnhO81OTgNSJ_zcrNaTWhSTV2Cy5TRO3SoPvyER6l-hAUVRCzQr3uuEMXxjIfutkYXJObFSMnzCjY0QUc34ONw813kyZdJu7UT9_0XruP_lu4mXO-1KTvsKtMt2PP1bbiy6Gff70AdaMhsScHtZUedZeuK0WB-u2UbgsD6ZtikHC2bT9-YCSVnFMLOwhKSBk_AKLOXL5mpS-ZM2-BVl8PKQ_yTOCm-uQunR29OXs_iPl9D7IRSKjbYGpY695x4kKn2HPumDhUer6zNvBCZQT2ZC2HzKjU-yaz1XvupVVNntBWc34P9el37B8BKl5VSGakISCdTpyuthU64xLNrk9sIXg7vrXA9zJxyaqyKoVODpSzC84vg-Wj6tSN4_M7oYHj5Re_ETUGgIJXrTKURPBt3o_vRnIqp_bpFGyWIqIMi-i82ORcZ6lKVRHC_q0_jnXBUhBIVQQT5Tk0bDQj_vbunXn4OGHCUhsTnl_gsQk36c-mKw_k8_Hj476ZP4ersZDEv5m-P3z-Ca3ipPs7zAPa3m9Y_Ri22tU-Cy_0AQUwvxg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb9QwEIdHpUgVF8qzBAoYxIFLVklsx7E4VZRVgW2FEJV6QIrsxIEVq2y12RzKX8-M86BLASFueUweTmbiX-zxZ4AX3MpCZmkUxiV1M6KgDjXK3BDFSWW4crGJaLzz8Ul6dCrencmzLXg1jIXp-BBjgxtFhv9eU4Cfl9WlIDeLxYT61NQ1uC7SKCOXPvz4kx2l-gYWFBChwLDusUKUxjMeulkZXVGYVxMlLwtYXwNNd-HzcO9d4sm3Sbu2k-L7L1jH_yzcLbjZK1N20LnSbdhy9R3YOe773u9C7VnIbE6p7WXHnGXLilFTfrtmK0LAumZYpRlaVl8umPEFZ5TAzvwAkgZPwGheL1cyU5esMG2DV50P4w5xI1FSXHMPTqdvPr0-CvvZGsJCKKVCg3VhqTPHiQYZa8fxz7RAfccraxMnRGJQTWZC2KyKjYsSa53TLrUqLYy2gvP7sF0va_cAWFkkpVRGKsLRybjQldZCR1zi2bXJbAAvh9eWFz3KnGbUWOTDLw2WMvfPL4Dno-l5x-_4ndH-8O7zPoSbnDBBKtOJigN4Nu7G4KMeFVO7ZYs2ShBPByX0X2wyLhJUpSoKYK9zp_FOOOpBiXoggGzD0UYDgn9v7qnnXz0EHIUh0fklPgvvSH8uXX4wm_mFh_9u-hR2PhxO89nbk_eP4AZeqU_y3Ift9ap1j1GIre0TH3A_ALRPLn4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+introduction+of+peanut+reduces+peanut+allergy+across+risk+groups+in+pooled+and+causal+inference+analyses&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Logan%2C+Kirsty&rft.au=Bahnson%2C+Henry+T.&rft.au=Ylescupidez%2C+Alyssa&rft.au=Beyer%2C+Kirsten&rft.date=2023-05-01&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=78&rft.issue=5&rft.spage=1307&rft.epage=1318&rft_id=info:doi/10.1111%2Fall.15597&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_all_15597 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon |